Dolphin 12.5 mg Suppository

Diclofenac sodium 12.5 mg.

ADDITIONAL INFORMATION

Composition: Each suppository contains: Active ingredients: Diclofenac sodium 12.5 mg.
Indications: Dolphin suppositories (Diclofenac sodium) is an anti-inflammatory. Antirheumatic, antipyretic and analgesic in different kinds of pains including:

  • – Adjuvant treatment in case of painful inflammatory infections of the ear e.g. Otitis and the throat e.g. pharingitis and tonsillitis together with the other prescribed drugs.
  • – Juvenile rheumatoid arthritis.
  • – After teeth extraction and after tonsillectomy.
  • – Painful post-operative inflammation and swelling.
  • – Painful syndrome of the back bone.
  • – Dolphin is used for anti-inflammatory and analgesic effects in the symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
Dosage and Administration: The dose is calculated according to the child body weight. The dose range is between 0.5 – 2 mg / kg body weight daily according to the severity of the case. And in case of Juvenile rheumatoid arthritis the dose can be increased to 3 mg / kg body weight daily on 2 –3 divided doses for maximum 4 days.
Package: Carton boxes contains 2(PVC) strip of 5 suppositories of 12.5 mg.
Facebook Page: https://www.facebook.com/Dolphinsuppositories/

Additional Information

human

human


Reviews

There are no reviews yet.

Be the first to review “Dolphin 12.5 mg Suppository”





Address


Delta Pharma

28 Farid St. Behined Meridien Heliopolis, Cairo, Egypt.



Delta Pharma Factory

Industrial Zone B4,10th of Ramadan City, Egypt.



Send Us


Telephone

info@dp.eg



Send C.V.

Send your CV to: careers@dp.eg


Contact


Telephone

(202) 24142500
(205) 54501211



Fax

(202) 24179962
(205) 54501256



Sales Department

+20 1111000656




DELTA PHARMA is a leading pharmaceutical company in the Egyptian market aiming to step up its rank among all other Arabian pharmaceutical manufacturers, to be one of the top ten generic companies in the region within the upcoming years.

© Copyright Delta Pharma 2024. All rights reserved.